High sensitivity C-reactive protein is associated with the metabolic syndrome independent to viral and bacterial pathogen burden

Diabetes Research and Clinical Practice

Volumn 84, Issue 3, 2009, Pages 296-302

  Ebrahimi, Abdolali ^a   Nabipour, Iraj ^a   Vahdat, Katayoun ^a   Jafari, Seyed Mojtaba ^a   Fouladvand, Moradali ^a   Assadi, Majid ^a   Movahed, Ali ^a   Obeidi, Narges ^a   Sanjdideh, Zahra ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C reactive protein; Inflammation; Insulin resistance; Metabolic; Pathogen burden

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN TISSUE; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VIRUS INFECTION;

ADULT; BACTERIAL INFECTIONS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; REFERENCE VALUES; REGRESSION ANALYSIS; RISK FACTORS; VIRUS DISEASES;

EID: 67349172132     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.03.010     Document Type: Article

References (40)

1. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
2. Dekker J.M., Girman C., Rhodes T., Nijpels G., Stehouwer C.D., Bouter L.M., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112 (2005) 666-673
3. Kip K.E., Marroquin O.C., Kelley D.E., Johnson B.D., Kelsey S.F., Shaw L.J., et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 109 (2004) 706-713
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III), J. Am. Med. Assoc. 285 (2001) 2486-2497.
5. Kopp H.P., Kopp C.W., Festa A., Krzyzanowska K., Kriwanek S., Minar E., et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1042-1047
6. McLaughlin T., Abbasi F., Lamendola C., Liang L., Reaven G., Schaaf P., et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106 (2002) 2908-2912
7. Ross R. Atherosclerosis-an inflammatory disease. N. Eng. J. Med. 340 (1999) 115-126
8. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., and Center for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association. Circulation 107 (2003) 499-511
9. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am. Heart J. 148 (2004) S19-26
10. Bullo M., Garcia-Lorda P., Megias I., and Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obesity Res. 11 (2003) 525-531
11. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
12. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
13. Frohlich M., Imhof A., Berg G., Hutchinson W.L., Pepys M.B., Boeing H., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23 (2000) 1835-1839
14. Ford E.S., Ajani U.A., and Mokdad A.H. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 28 (2005) 878-881
15. Lambert M., Delvin E.E., Paradis G., O'Loughlin J., Hanley J.A., and Levy E. C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin. Chem. 50 (2004) 1762-1768
16. Martinez M.A., Puig J.G., Mora M., Aragon R., O'Dogherty P., Anton J.L., et al. Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid RIesgo Cardiovascular) Study. Metabolism 57 (2008) 1232-1240
17. Ishikawa S., Kayaba K., Gotoh T., Nakamura Y., and Kajii E. Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ. J. 71 (2007) 26-31
18. Than T.S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M.E., and Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (2002) 2016-2021
19. Laaksonen D.E., Niskanen L., Nyyssonen K., Punnonen K., Tuomainen T.P., Valkonen V.P., et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47 (2004) 1403-1410
20. Onat A., Can G., and Hergenc G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism 57 (2008) 207-214
21. Ridker P.M., Wilson P.W.F., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
22. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 97 (2006) 3A-11A
23. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Rev. 24 (2003) 278-301
24. Fernandez-Real J.M., Lopez-Bermejo A., Vendrell J., Ferri M.J., Recasens M., and Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care 29 (2006) 1058-1064
25. Dai D., Lin J., Kao J., Hsu C., Chiang F., Lin J., et al. The effect of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular events. Clin. Endocrinol. Metab. 92 (2007) 2532-2537
26. Howard B.V., Best L., Comuzzie A., Ebbesson S.O., Epstein S.E., Fabsitz R.R., et al. C-reactive protein, insulin resistance, and metabolic syndrome in a population with a high burden of subclinical infection: insight from the GOCADAN Study. Diabetes Care 16 (2008 Sep) Epub ahead of print
27. Nabipour I., Vahdat K., Jafari S.M., Pazoki R., and Sanjdideh Z. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart Study. Cardiovasc. Diabet. 5 (2006) 25
28. Nabipour I., Vahdat K., Jafari S.M., Beigi S., Assadi M., Azizi F., et al. Elevated high sensitivity C-reactive protein is associated with type 2 diabetes mellitus: the Persian Gulf Healthy Heart Study. Endocrine J. 55 (2008) 717-722
29. Centers for Disease Control and Prevention (CDC), Prevalence of physical activity including lifestyle activities among adults-United States, 2000-2001, MMWR. Morb. Mortal. 52 (2003) 764-769.
30. Epstein S.E., Zhou Y.F., and Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 100 (1999) e20-228
31. Rupprecht H.J., Blankenberg S., Bickel C., Rippin G., Hafner G., Prellwitz W., et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 104 1 (2001) 25-31
32. Liu L., Liu Y., Tong W., Tong W., Ye H., Zhang X., et al. Pathogen burden in essential hypertension. Circ. J. 71 11 (2007) 1761-1764
33. Devaraj S., Rosenson R.S., and Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol. Metabol. Clin. North America 33 (2004) 431-453
34. Ridker P.M., Pare G., Parker A., Zee R.Y.L., Danik J.S., Buring J.E., et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am. J. Hum. Genet. 82 (2008) 1185-1192
35. Matsuo Y., Hashizume T., Shioji S., and Akasaka T. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease. Circ. J. 72 (2008) 2046-2050
36. Saltevo J., Vanhala M., Kautiainen H., Kumpusalo E., and Laakso M. Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome. Mediators Inflamm. 2007 (2007) 93573
37. Mauger J.F., Levesque J., Paradis M.E., Paradis M., Bergeron N., Tchernof A., et al. Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome. J. Clin. Endocrinol. Metab. 93 (2008) 3158-3164
38. Finch C.E., and Morgan T.E. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr. Alzheimer Res. 4 (2007) 185-189
39. Dik M.G., Jonker C., Comijs H.C., Deeg D.J.H., Kok A., Yaffe K., et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 30 (2007) 2655-2660
40. Yaffe K. Metabolic syndrome and cognitive decline. Curr. Alzheimer Res. 4 (2007) 123-126